Structure/function studies of immunogen recognition by anti-HIV antibody b12

抗HIV抗体b12免疫原识别的结构/功能研究

• 批准号: 8117982
• 负责人: Roland K Strong
• 金额: $ 53.84万
• 依托单位: SEATTLE BIOMEDICAL RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-05-01 至 2016-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8117982
• 关键词: AIDS Vaccines; Affect; Affinity; Antibodies; Antibody Binding Sites; Antibody Formation; Antigens; Applied Research; B-Cell Activation; B-Lymphocytes; Back; Basic Science; Binding; Binding Sites; Biological Assay; Characteristics; Complement; Complex; Crystallization; Crystallography; Data; Development; Engineering; Epitopes; Event; Generations; Goals; HIV; HIV Antibodies; HIV Envelope Protein gp120; HIV Infections; HIV vaccine; Highly Active Antiretroviral Therapy; Immune response; Immune system; Immunization; Immunodominant Epitopes; Immunoglobulin Somatic Hypermutation; Immunology; In Vitro; Infection; Kinetics; Laboratories; Lead; Membrane; Molecular; Molecular Conformation; Pharmaceutical Preparations; Plasma Cells; Process; Property; Proteins; Receptor Signaling; Receptors, Antigen, B-Cell; Research; Scaffolding Protein; Structure; Structure of germinal center of lymph node; Testing; Thermodynamics; Vaccines; Viral; Viral Vaccines; Virus; Virus Diseases; Virus Receptors; Washington; antigen binding; base; design; feeding; improved; in vivo; inhibiting antibody; neutralizing antibody; neutralizing monoclonal antibodies; novel vaccines; prevent; prophylactic; protein protein interaction; response; scaffold; vaccine candidate; vaccine development

Effective AIDS vaccines will likely need to elicit antibodies that can neutralize diverse strains of HIV, but vaccine immunogens based on soluble HIV Env constructs have, so far, failed to elicit such responses. Our first-generation attempts to design 'epitope-scaffold' antigens for bNAb 4E10 generate exquisite epitope-specific responses that, unfortunately, also fail to potently neutralize HIV. In order to improve on this approach (and embrace parallel strategies), we will now focus on the broadly neutralizing, CD4-binding site antibody b12. We propose to iteratively engineer b12-specific i) epitope-scaffolds and ii) minimized gp120 constructs, with binding optimized to both mature b12 and its germline precursor; the latter recognition event is essential for selectively activating the correct naive B cells that will lead to b12-equivalent responses. The biophysical parameters describing BCR/antigen interactions (affinities, kinetics, thermodynamics) have been shown to have profound effects on the course of humoral immune responses. We will test the hypothesis that i) b12 germline candidates will not completely recapitulate the binding, structural or neutralization properties of the mature antibody by some subset of the parameters that describe protein/protein interactions and function and ii) that, in order for designed immunogens to induce effective b12-like responses upon immunization, both immunogen/b12 and immunogen/germline interactions will need to be recapitulated. Since no single b12 germline precursor can confidently be identified, we propose to study the structures (using x-ray crystallography and small-angle x-ray scattering (SAXS)) and binding properties (using SPR and ITC) of an ensemble of the 12 likeliest candidates. Our proposed comprehensive biophysical studies of mature b12 and the complete ensemble of candidate b12 germline precursor antibodies will: i) support the rational immunogen redesign cycle in Project 1; ii) detail the molecular mechanisms of b12 maturation; and iii) provide the biophysical framework for interpreting the in vitro and in vivo B cell activation assays in Project 3. Our research goal is to understand the biophysical constraint/s on B cell activation thresholds for an epitope of one of the most potent and broadly anti-HlV-1 neutralizing MAbs known. We will then use these results to guide efforts to rationally design better immunogens to elicit anti-HIV NAbs while contributing significantly to the field of fundamental B cell immunology, combining basic and applied research goals.

有效的艾滋病疫苗可能需要引发能够中和不同HIV毒株的抗体，但迄今为止，基于可溶性HIV Env构建体的疫苗免疫原未能引发这种反应。我们的第一代尝试为bNAb 4 E10设计“表位支架”抗原，产生了精致的表位特异性反应，不幸的是，也未能有效地中和HIV。为了改进这种方法（并采用平行策略），我们现在将重点放在广泛中和的CD 4结合位点上。 抗体B12。我们建议迭代工程化b12特异性i）表位支架和ii）最小化gp 120构建体，并优化与成熟b12及其种系前体的结合;后者的识别事件对于选择性激活正确的幼稚B细胞至关重要，这将导致b12等效反应。描述BCR/抗原相互作用的生物物理参数（亲和力、动力学、热力学）已被证明对体液免疫应答过程具有深远影响。我们将检验以下假设：i）b12生殖系候选物将不完全概括结合、结构或中和 通过描述蛋白质/蛋白质相互作用和功能的参数的某些子集确定成熟抗体的特性，和ii）为了使设计的免疫原在免疫后诱导有效的B12样应答，需要概括免疫原/B12和免疫原/种系相互作用。 由于没有一个单一的b12种系前体可以确定，我们建议研究的结构（使用X射线晶体学和小角X射线散射（SAXS））和结合性能（使用SPR和ITC）的12个最有可能的候选人的合奏。我们提出的全面的生物物理研究， 成熟b12和候选b12种系前体抗体的完整集合将：i）支持项目1中的合理免疫原重新设计循环; ii）详述b12成熟的分子机制;和iii）提供用于解释项目3中的体外和体内B细胞活化测定的生物物理框架。我们的研究目标是了解已知的最有效和最广泛的抗HIV-1中和MAb之一的表位对B细胞活化阈值的生物物理约束。然后，我们将使用这些结果来指导合理设计更好的免疫原，以引发抗HIV NAb，同时为人类免疫系统的发展做出贡献。 这对基础B细胞免疫学领域具有重要意义，结合了基础和应用研究目标。